Cargando…
Mortality and admission to intensive care units after febrile neutropenia in patients with cancer
Febrile neutropenia (FN) is a critical complication of chemotherapy associated with increased in‐hospital mortality. However, associations with increased mortality and intensive care unit (ICU) admissions during longer follow‐up are not established. Patients treated with standard first‐line chemothe...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196064/ https://www.ncbi.nlm.nih.gov/pubmed/32144897 http://dx.doi.org/10.1002/cam4.2955 |
_version_ | 1783528649159344128 |
---|---|
author | Aagaard, Theis Reekie, Joanne Jørgensen, Mette Roen, Ashley Daugaard, Gedske Specht, Lena Sengeløv, Henrik Mocroft, Amanda Lundgren, Jens Helleberg, Marie |
author_facet | Aagaard, Theis Reekie, Joanne Jørgensen, Mette Roen, Ashley Daugaard, Gedske Specht, Lena Sengeløv, Henrik Mocroft, Amanda Lundgren, Jens Helleberg, Marie |
author_sort | Aagaard, Theis |
collection | PubMed |
description | Febrile neutropenia (FN) is a critical complication of chemotherapy associated with increased in‐hospital mortality. However, associations with increased mortality and intensive care unit (ICU) admissions during longer follow‐up are not established. Patients treated with standard first‐line chemotherapy for solid cancers at Rigshospitalet, Denmark in 2010‐2016 were included. Incidence rate ratios (IRR) of all‐cause, infectious and cardiovascular mortality, and ICU admissions after FN were analyzed by Poisson regression. Risk factors at the time of FN were analyzed in the subpopulation of patients with FN; all‐cause mortality was further stratified by the time periods 0‐30, 31‐365, and 366+ days after FN. We included 9018 patients with gastric (14.4%) and breast (13.1%) cancer being the most common, 51.2% had locally advanced or disseminated disease and the patients had a median Charlson Comorbidity Index score of 0 (interquartile range, 0‐0). During follow‐up, 845 (9.4%) experienced FN and 4483 (49.7%) died during 18 775 person‐years of follow‐up. After adjustment, FN was associated with increased risk of all‐cause mortality, infectious mortality, and ICU admissions with IRRs of 1.39 (95% CI, 1.24‐1.56), 1.94 (95% CI, 1.43‐2.62), and 2.28 (95% CI, 1.60‐3.24). Among those with FN, having a positive blood culture and low lymphocytes were associated with excess risk of death and ICU admissions (predominantly the first 30 days after FN), while elevated C‐reactive protein and low hemoglobin predicted mortality the first year after FN. The risk of death varied according to the time since FN; adjusted IRR per additional risk factor present for the time periods 0‐30, 31‐365, and 366+ days after FN were 2.00 (95% CI, 1.45‐2.75), 1.36 (95% CI, 1.17‐1.57), and 1.17 (95% CI, 0.98‐1.41). FN was associated with increased mortality and risk of ICU admissions. An objectively identifiable subgroup of patients among those with FN carried this excess risk. |
format | Online Article Text |
id | pubmed-7196064 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71960642020-05-04 Mortality and admission to intensive care units after febrile neutropenia in patients with cancer Aagaard, Theis Reekie, Joanne Jørgensen, Mette Roen, Ashley Daugaard, Gedske Specht, Lena Sengeløv, Henrik Mocroft, Amanda Lundgren, Jens Helleberg, Marie Cancer Med Clinical Cancer Research Febrile neutropenia (FN) is a critical complication of chemotherapy associated with increased in‐hospital mortality. However, associations with increased mortality and intensive care unit (ICU) admissions during longer follow‐up are not established. Patients treated with standard first‐line chemotherapy for solid cancers at Rigshospitalet, Denmark in 2010‐2016 were included. Incidence rate ratios (IRR) of all‐cause, infectious and cardiovascular mortality, and ICU admissions after FN were analyzed by Poisson regression. Risk factors at the time of FN were analyzed in the subpopulation of patients with FN; all‐cause mortality was further stratified by the time periods 0‐30, 31‐365, and 366+ days after FN. We included 9018 patients with gastric (14.4%) and breast (13.1%) cancer being the most common, 51.2% had locally advanced or disseminated disease and the patients had a median Charlson Comorbidity Index score of 0 (interquartile range, 0‐0). During follow‐up, 845 (9.4%) experienced FN and 4483 (49.7%) died during 18 775 person‐years of follow‐up. After adjustment, FN was associated with increased risk of all‐cause mortality, infectious mortality, and ICU admissions with IRRs of 1.39 (95% CI, 1.24‐1.56), 1.94 (95% CI, 1.43‐2.62), and 2.28 (95% CI, 1.60‐3.24). Among those with FN, having a positive blood culture and low lymphocytes were associated with excess risk of death and ICU admissions (predominantly the first 30 days after FN), while elevated C‐reactive protein and low hemoglobin predicted mortality the first year after FN. The risk of death varied according to the time since FN; adjusted IRR per additional risk factor present for the time periods 0‐30, 31‐365, and 366+ days after FN were 2.00 (95% CI, 1.45‐2.75), 1.36 (95% CI, 1.17‐1.57), and 1.17 (95% CI, 0.98‐1.41). FN was associated with increased mortality and risk of ICU admissions. An objectively identifiable subgroup of patients among those with FN carried this excess risk. John Wiley and Sons Inc. 2020-03-07 /pmc/articles/PMC7196064/ /pubmed/32144897 http://dx.doi.org/10.1002/cam4.2955 Text en © 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Cancer Research Aagaard, Theis Reekie, Joanne Jørgensen, Mette Roen, Ashley Daugaard, Gedske Specht, Lena Sengeløv, Henrik Mocroft, Amanda Lundgren, Jens Helleberg, Marie Mortality and admission to intensive care units after febrile neutropenia in patients with cancer |
title | Mortality and admission to intensive care units after febrile neutropenia in patients with cancer |
title_full | Mortality and admission to intensive care units after febrile neutropenia in patients with cancer |
title_fullStr | Mortality and admission to intensive care units after febrile neutropenia in patients with cancer |
title_full_unstemmed | Mortality and admission to intensive care units after febrile neutropenia in patients with cancer |
title_short | Mortality and admission to intensive care units after febrile neutropenia in patients with cancer |
title_sort | mortality and admission to intensive care units after febrile neutropenia in patients with cancer |
topic | Clinical Cancer Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196064/ https://www.ncbi.nlm.nih.gov/pubmed/32144897 http://dx.doi.org/10.1002/cam4.2955 |
work_keys_str_mv | AT aagaardtheis mortalityandadmissiontointensivecareunitsafterfebrileneutropeniainpatientswithcancer AT reekiejoanne mortalityandadmissiontointensivecareunitsafterfebrileneutropeniainpatientswithcancer AT jørgensenmette mortalityandadmissiontointensivecareunitsafterfebrileneutropeniainpatientswithcancer AT roenashley mortalityandadmissiontointensivecareunitsafterfebrileneutropeniainpatientswithcancer AT daugaardgedske mortalityandadmissiontointensivecareunitsafterfebrileneutropeniainpatientswithcancer AT spechtlena mortalityandadmissiontointensivecareunitsafterfebrileneutropeniainpatientswithcancer AT sengeløvhenrik mortalityandadmissiontointensivecareunitsafterfebrileneutropeniainpatientswithcancer AT mocroftamanda mortalityandadmissiontointensivecareunitsafterfebrileneutropeniainpatientswithcancer AT lundgrenjens mortalityandadmissiontointensivecareunitsafterfebrileneutropeniainpatientswithcancer AT hellebergmarie mortalityandadmissiontointensivecareunitsafterfebrileneutropeniainpatientswithcancer |